Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (31-40 of 138) with videos related to

Pageof 14
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Molecular Testing in Breast CancerJennifer K Litton, Harold J Burstein, Nicholas C Turner
Cancer Discovery|July 3, 2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast CancerJoline S J Lim, Nicholas C Turner, Timothy A Yap
Nature Reviews. Drug Discovery|January 31, 2015
The history and future of targeting cyclin-dependent kinases in cancer therapyUzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, et al.
DNA Repair|October 4, 2008
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityChristopher J Lord, Sarah McDonald, Sally Swift, et al.
The Lancet. Oncology|March 28, 2024
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancerIseult M Browne, Fabrice André, Sarat Chandarlapaty, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2023
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic InterceptionArielle J Medford, Beverly Moy, Laura M Spring, et al.
Clinical Breast Cancer|July 15, 2022
Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-ResistanceAlicia F C Okines, Tazia Irfan, Kabir Mohammed, et al.
Cancer Discovery|June 8, 2013
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancerMaria Teresa Herrera-Abreu, Alex Pearson, James Campbell, et al.
Molecular Cancer Therapeutics|February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR PathwaysMarieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
Pageof 14

Showing results (31-40 of 138) with videos related to

Sort By:
Pageof 14
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Molecular Testing in Breast CancerJennifer K Litton, Harold J Burstein, Nicholas C Turner
Cancer Discovery|July 3, 2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast CancerJoline S J Lim, Nicholas C Turner, Timothy A Yap
Nature Reviews. Drug Discovery|January 31, 2015
The history and future of targeting cyclin-dependent kinases in cancer therapyUzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, et al.
DNA Repair|October 4, 2008
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityChristopher J Lord, Sarah McDonald, Sally Swift, et al.
The Lancet. Oncology|March 28, 2024
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancerIseult M Browne, Fabrice André, Sarat Chandarlapaty, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2023
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic InterceptionArielle J Medford, Beverly Moy, Laura M Spring, et al.
Clinical Breast Cancer|July 15, 2022
Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-ResistanceAlicia F C Okines, Tazia Irfan, Kabir Mohammed, et al.
Cancer Discovery|June 8, 2013
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancerMaria Teresa Herrera-Abreu, Alex Pearson, James Campbell, et al.
Molecular Cancer Therapeutics|February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR PathwaysMarieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
Pageof 14